Metabomed is developing a therapeutic strategy based on new drugs that inhibit metabolic enzymes which are vital for cancer cells’ survival
Location: Israel, Center District, Yavne
Employees: 11-50
Founded date: 2013
Investors 2
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 3
| Date | Title | Description |
| 09.09.2020 | MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer | CAMBRIDGE, Mass. and YAVNE, Israel, Sept. 9, 2020 /PRNewswire/ -- MetaboMed, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced the appointment of Ali Fattaey, Ph... |
| 19.12.2019 | Metabomed Completes a $12.5 Million Raise | Metabomed, a leading cancer metabolism company completed a financing of $12.5 million bringing the total raised to date to $30 million. The company announced that it has declared a clinical candidate for its first-in-class program targeting... |
| 04.04.2016 | Metabomed Raises $18M in Series A Funding | Metabomed Ltd, a Yavne, Israel-based cancer metabolism company, completed an extension of its Series A round bringing the total of its raise to $18m. Backers included existing investors MS Ventures, Boehringer Ingelheim Venture Fund (BIVF),... |